Stock Track | HENLIUS Plummets 10.53% as Shareholders Reject Fosun's Buyout Offer

Stock Track

Jan 23, 2025

Shares of HENLIUS (02696) plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.

The rejected offer, which valued the drugmaker at HK$13.37 billion ($1.72 billion), proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.

The sharp decline in HENLIUS's stock price reflects investors' disappointment with the failed buyout attempt. The rejection of the offer raises concerns about the company's future prospects and potential challenges in securing alternative funding or strategic partnerships.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1144209471"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144209471\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144209471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144209471","market":"hk","top_or_hot":-1,"title":"Stock Track | HENLIUS Plummets 10.53% as Shareholders Reject Fosun's Buyout Offer","media":"Stock Track","content":"<p>Shares of HENLIUS (02696) plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.</p>\n\n<p>The rejected offer, which valued the drugmaker at HK$13.37 billion ($1.72 billion), proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.</p>\n\n<p>The sharp decline in HENLIUS's stock price reflects investors' disappointment with the failed buyout attempt. The rejection of the offer raises concerns about the company's future prospects and potential challenges in securing alternative funding or strategic partnerships.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HENLIUS Plummets 10.53% as Shareholders Reject Fosun's Buyout Offer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HENLIUS Plummets 10.53% as Shareholders Reject Fosun's Buyout Offer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-23 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of HENLIUS (02696) plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.</p>\n\n<p>The rejected offer, which valued the drugmaker at HK$13.37 billion ($1.72 billion), proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.</p>\n\n<p>The sharp decline in HENLIUS's stock price reflects investors' disappointment with the failed buyout attempt. The rejection of the offer raises concerns about the company's future prospects and potential challenges in securing alternative funding or strategic partnerships.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1144209471","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144209471","pubTimestamp":1737597290,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of HENLIUS  plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.The rejected offer, which valued the drugmaker at HK$13.37 billion , proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"股票赛道复宏汉霖暴跌10.53%股东拒绝复星收购要约","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shares of HENLIUS (02696) plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.\nThe rejected offer, which valued the drugmaker at HK$13.37 billion ($1.72 billion), proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.\nThe sharp decline in HENLIUS's stock price reflects investors' disappointment with the failed buyout attempt. The rejection of the offer raises concerns about the company's future prospects and potential challenges in securing alternative funding or strategic partnerships.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"merge,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}